• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与慢性阻塞性肺疾病相关的肺外合并症:综述。

Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.

机构信息

School of Medical and Life Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610000, People's Republic of China.

Department of Respiratory and Critical Care Medicine, Suining Central Hospital, Suining, Sichuan, 629000, People's Republic of China.

出版信息

Int J Chron Obstruct Pulmon Dis. 2024 Feb 29;19:567-578. doi: 10.2147/COPD.S447739. eCollection 2024.

DOI:10.2147/COPD.S447739
PMID:38476124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10927883/
Abstract

Most patients with chronic obstructive pulmonary disease (COPD) suffer from at least one additional, clinically relevant chronic disease. To a degree, the high global prevalence and mortality rate of COPD is closely related to its extrapulmonary effects. Moreover, the various of comorbidities of COPD and itself interact with each other, resulting in diverse clinical manifestations and individual differences, and thus further influencing the prognosis as well as healthcare burden of COPD patients. This is closely related to the common risk factors of chronic diseases (aging, smoking, inactivity, etc.). Additionally, some pathophysiological mechanisms caused by COPD, including the systemic inflammatory response, hypoxia, oxidative stress, and others, also have an impact on other systems. But comprehensive management and medical interventions have not yet been established. The clinicians should improve their knowledge and skills in diagnosing as well as treating the comorbidities of COPD, and then aim to develop more individualized, efficient diagnostic and therapeutic strategies for different patients to achieve greater clinical benefits. In this article, we will review the risk factors, mechanisms, and treatment strategies for extrapulmonary comorbidities in chronic obstructive pulmonary disease, including cardiovascular diseases, diabetes, anemia, osteoporosis, emotional disorders, and gastroesophageal reflux disease.

摘要

大多数慢性阻塞性肺疾病(COPD)患者至少患有一种其他临床相关的慢性病。在某种程度上,COPD 的高全球患病率和死亡率与其肺外效应密切相关。此外,COPD 和自身的各种合并症相互作用,导致不同的临床表现和个体差异,从而进一步影响 COPD 患者的预后和医疗负担。这与慢性疾病的常见危险因素(衰老、吸烟、不活动等)密切相关。此外,COPD 引起的一些病理生理机制,包括全身炎症反应、缺氧、氧化应激等,也会对其他系统产生影响。但尚未建立全面的管理和医疗干预措施。临床医生应提高对 COPD 合并症的诊断和治疗的认识和技能,然后努力为不同患者制定更个体化、有效的诊断和治疗策略,以实现更大的临床获益。本文将综述慢性阻塞性肺疾病肺外合并症的危险因素、发病机制和治疗策略,包括心血管疾病、糖尿病、贫血、骨质疏松症、情绪障碍和胃食管反流病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg

相似文献

1
Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.与慢性阻塞性肺疾病相关的肺外合并症:综述。
Int J Chron Obstruct Pulmon Dis. 2024 Feb 29;19:567-578. doi: 10.2147/COPD.S447739. eCollection 2024.
2
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果:面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
3
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者自我管理干预措施(包括针对病情加重的行动计划)与常规护理的比较。
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2.
4
Self-management interventions for people with chronic obstructive pulmonary disease.针对慢性阻塞性肺疾病患者的自我管理干预措施。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
Vitamin D for the management of chronic obstructive pulmonary disease.维生素D用于慢性阻塞性肺疾病的管理
Cochrane Database Syst Rev. 2024 Sep 27;9(9):CD013284. doi: 10.1002/14651858.CD013284.pub2.

引用本文的文献

1
The Lung-Brain Axis in Chronic Obstructive Pulmonary Disease-Associated Neurocognitive Dysfunction: Mechanistic Insights and Potential Therapeutic Options.慢性阻塞性肺疾病相关神经认知功能障碍中的肺-脑轴:机制洞察与潜在治疗选择
Int J Biol Sci. 2025 May 15;21(8):3461-3477. doi: 10.7150/ijbs.109261. eCollection 2025.
2
Exercise Dysfunction and Pulmonary Rehabilitation Strategies in COPD Patients at High-Altitudes: A Review.高海拔慢性阻塞性肺疾病患者的运动功能障碍与肺康复策略:综述
Int J Chron Obstruct Pulmon Dis. 2025 Jun 5;20:1807-1817. doi: 10.2147/COPD.S506552. eCollection 2025.
3
Prevalence of chronic respiratory disease using case-finding tools in adults living with noncommunicable disease in low- and middle-income countries: a systematic review.

本文引用的文献

1
Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves.非经典靶器官的糖尿病微血管病变:视网膜、肾脏和周围神经之外的隐匿性影响。
Cardiovasc Diabetol. 2023 Nov 15;22(1):314. doi: 10.1186/s12933-023-02056-3.
2
Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products.糖尿病性肺功能障碍中的非凋亡程序性细胞死亡:晚期糖基化终产物的新作用。
Front Endocrinol (Lausanne). 2023 Oct 26;14:1126661. doi: 10.3389/fendo.2023.1126661. eCollection 2023.
3
The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum.
使用病例发现工具在低收入和中等收入国家患有非传染性疾病的成年人中慢性呼吸道疾病的患病率:一项系统综述
BMC Pulm Med. 2025 May 10;25(1):232. doi: 10.1186/s12890-025-03697-8.
4
Maximal Forced Inspiratory Flow Dynamics and Acute Exacerbation in Chronic Obstructive Pulmonary Disease Patients with Exacerbation History.有加重病史的慢性阻塞性肺疾病患者的最大用力吸气流量动力学与急性加重
Tuberc Respir Dis (Seoul). 2025 Jul;88(3):535-544. doi: 10.4046/trd.2024.0156. Epub 2025 Mar 28.
5
Unmasking Cardiovascular Risk in Patients with COPD at Primary Care Settings: The Critical Role of Age, Sex, and Smoking.在基层医疗环境中揭示慢性阻塞性肺疾病患者的心血管风险:年龄、性别和吸烟的关键作用。
J Clin Med. 2025 Feb 21;14(5):1444. doi: 10.3390/jcm14051444.
6
Carbon Monoxide Poisoning: Diagnosis, Prognostic Factors, Treatment Strategies, and Future Perspectives.一氧化碳中毒:诊断、预后因素、治疗策略及未来展望
Diagnostics (Basel). 2025 Feb 27;15(5):581. doi: 10.3390/diagnostics15050581.
7
The Role of Trace Elements in COPD: Pathogenetic Mechanisms and Therapeutic Potential of Zinc, Iron, Magnesium, Selenium, Manganese, Copper, and Calcium.微量元素在慢性阻塞性肺疾病中的作用:锌、铁、镁、硒、锰、铜和钙的发病机制及治疗潜力
Nutrients. 2024 Nov 28;16(23):4118. doi: 10.3390/nu16234118.
8
Artificial Intelligence in Chronic Obstructive Pulmonary Disease: Research Status, Trends, and Future Directions --A Bibliometric Analysis from 2009 to 2023.人工智能在慢性阻塞性肺疾病中的应用:研究现状、趋势和未来方向——2009 年至 2023 年的文献计量分析。
Int J Chron Obstruct Pulmon Dis. 2024 Aug 21;19:1849-1864. doi: 10.2147/COPD.S474402. eCollection 2024.
9
HTR2B as a novel biomarker of chronic obstructive pulmonary disease with lung squamous cell carcinoma.HTR2B 作为慢性阻塞性肺疾病伴肺鳞癌的新型生物标志物。
Sci Rep. 2024 Jun 8;14(1):13206. doi: 10.1038/s41598-024-63896-x.
铁剂治疗对炎症性肠病氧化应激和肠道微生物群的影响:困境综述。
Redox Biol. 2023 Dec;68:102950. doi: 10.1016/j.redox.2023.102950. Epub 2023 Oct 30.
4
COPD and multimorbidity: recognising and addressing a syndemic occurrence.COPD 与多种共病:识别和应对综合征发生。
Lancet Respir Med. 2023 Nov;11(11):1020-1034. doi: 10.1016/S2213-2600(23)00261-8. Epub 2023 Sep 8.
5
Relationship between serum Th1/Th2 imbalance and depression in elderly patients with COPD and its clinical implications.老年 COPD 患者血清 Th1/Th2 失衡与抑郁的关系及其临床意义。
Technol Health Care. 2023;31(6):2047-2058. doi: 10.3233/THC-230665.
6
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial.针对 COPD 患者焦虑或抑郁的个体化心理干预(TANDEM):一项随机对照试验。
Eur Respir J. 2023 Nov 2;62(5). doi: 10.1183/13993003.00432-2023. Print 2023 Nov.
7
Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).基质金属蛋白酶抑制剂在癌症治疗中的应用:更新综述(2013-2023)。
Molecules. 2023 Jul 21;28(14):5567. doi: 10.3390/molecules28145567.
8
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.地舒单抗、特立帕肽和口服双膦酸盐预防糖皮质激素性骨质疏松症的临床疗效:系统评价和荟萃分析。
J Orthop Surg Res. 2023 Jun 22;18(1):447. doi: 10.1186/s13018-023-03920-4.
9
Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD.质子泵抑制剂治疗胃食管反流病对 COPD 患者急性加重和肺炎风险的影响。
Respir Res. 2023 Mar 11;24(1):75. doi: 10.1186/s12931-023-02345-1.
10
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告:《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.